SLC5A2 and Hypoglycemia: Among the seven RCTs, six trials provided data on the RR for adverse events, enabling a pooled analysis to compare the safety outcomes, including any adverse events, hypoglycemia, UTIs, and AKI between SGLT2 inhibitors and placebo groups.